[go: up one dir, main page]

GT200600296A - Derivados de n-[(1,5-fenil-1h-pirazol-3-il)-metil] sulfonamida, su preparación y su aplicación en terapeutica - Google Patents

Derivados de n-[(1,5-fenil-1h-pirazol-3-il)-metil] sulfonamida, su preparación y su aplicación en terapeutica

Info

Publication number
GT200600296A
GT200600296A GT200600296A GT200600296A GT200600296A GT 200600296 A GT200600296 A GT 200600296A GT 200600296 A GT200600296 A GT 200600296A GT 200600296 A GT200600296 A GT 200600296A GT 200600296 A GT200600296 A GT 200600296A
Authority
GT
Guatemala
Prior art keywords
derivatives
pirazol
sulfonamide
preparation
fenil
Prior art date
Application number
GT200600296A
Other languages
English (en)
Inventor
Francis Barth
Christian Congy
Serge Martinez
Philippe Pointeau
Murielle Rinaldi-Camona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600296A publication Critical patent/GT200600296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCIÓN DESCRIBE LA PREPARACIÓN Y USO TERAPÉUTICO DE LOS DERIVADOS DE N-[(1,5-DIFENIL-1H-PIRAZOL-3-IL-)METIL]-SULFONAMIDA, DESCRITOS EN LA FÓRMULA GENERAL (I). ESTOS SON NUEVOS DERIVADOS SUSITUIDOS QUE TIENEN PROPIEDADES ANTAGONISTAS DE LOS RECEPTORES CB1 DE CANABINOIDES, LOCALIZADOS A NIVEL CENTRAL Y/O PERIFÉRICO.
GT200600296A 2005-07-08 2006-07-06 Derivados de n-[(1,5-fenil-1h-pirazol-3-il)-metil] sulfonamida, su preparación y su aplicación en terapeutica GT200600296A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507360A FR2888236B1 (fr) 2005-07-08 2005-07-08 Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
GT200600296A true GT200600296A (es) 2007-03-14

Family

ID=35872804

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600296A GT200600296A (es) 2005-07-08 2006-07-06 Derivados de n-[(1,5-fenil-1h-pirazol-3-il)-metil] sulfonamida, su preparación y su aplicación en terapeutica

Country Status (7)

Country Link
AR (1) AR057660A1 (es)
DO (1) DOP2006000163A (es)
FR (1) FR2888236B1 (es)
GT (1) GT200600296A (es)
PE (1) PE20070175A1 (es)
TW (1) TW200800910A (es)
UY (1) UY29657A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297710B1 (en) 2006-07-12 2007-11-20 Sanofi-Aventis Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
FR2911136B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
CN113200850A (zh) * 2021-05-08 2021-08-03 渭南师范学院 一种α-酰氧基酮化合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
UY29657A1 (es) 2007-01-31
AR057660A1 (es) 2007-12-12
FR2888236B1 (fr) 2007-09-21
PE20070175A1 (es) 2007-02-23
TW200800910A (en) 2008-01-01
DOP2006000163A (es) 2007-02-15
FR2888236A1 (fr) 2007-01-12

Similar Documents

Publication Publication Date Title
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EA200870409A1 (ru) Антагонисты киназы pi3
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
DE602004012564D1 (de) Chinolin- und chinazolinderivate mit affinität für rezeptoren vom 5ht1-typ
ATE383856T1 (de) (4-hydroxyphenyl)-1h-indol-3-carbaldehydoxim- derivative als östrogenagentien
EP1605936A4 (en) ARYL-spiro hydantoin-CGRP Receptor Antagonists
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
CY1110262T1 (el) Υποκαθισταμενες ενωσεις πιπεριδινης για χρηση ως ανταγωνιστες του υποδοχεα η3 της ισταμινης
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
BRPI0809795A2 (pt) "antagonistas do trpv1 e usos deste".
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
BRPI0615898B8 (pt) composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
ATE493412T1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
NO20024932D0 (no) Kontrastmiddel
UY28519A1 (es) Derivados de quinazolina
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
EP1871752A4 (en) ANTAGONISTS OF THE AMIDOPROPOXYPHENYLOREXIN RECEPTOR
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
EP1827421A4 (en) Estrogen receptor modulators
CY1111983T1 (el) Φαρμακευτικη συνθεση και μεθοδος χρησης αντιμυκητιακου παραγοντα σε συνδυασμο
EP1670483A4 (en) 17-heterocyclic 4-azasteroid derivatives as androgen receptor modules
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.